Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry
The Journal of Finance · 2024-06 · 79 (3) · 2195-2236
DOI: 10.1111/jofi.13321 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Finance, 2024-03. Verfasst von ALICE BONAIMÉ und 1 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Using novel data from the pharmaceutical industry, we study product prices and innovation around mergers. Exploiting within‐deal variation in product market consolidation, we show that prices increase more for drugs in consolidating markets than for matched control drugs. Estimates indicate a 2% average price effect that persists for about one year. Price increases expand with acquirer‐target product similarity and are more pronounced within less competitive product markets with fewer players and no generic competition. Examination of trade‐offs reveals these deals generate significant shareholder value. They also spur labeling and other manufacturing‐related innovation, but not the development of new drugs.
Zitieren
APA
BONAIMÉ, A., & WANG, Y. E. (2024). Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry. The Journal of Finance, 79(3), 2195-2236. https://doi.org/10.1111/jofi.13321
Vancouver
BONAIMÉ A, WANG YE. Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry. The Journal of Finance. 2024;79(3):2195-2236. doi:10.1111/jofi.13321
BibTeX
@article{BONAIM2024,
author = {BONAIMÉ, ALICE and WANG, YE (EMMA)},
title = {Mergers, Product Prices, and Innovation: Evidence from the Pharmaceutical Industry},
journal = {The Journal of Finance},
year = {2024},
volume = {79},
number = {3},
pages = {2195--2236},
doi = {10.1111/jofi.13321}
}
EUVIMED